MHL, a non-profit organization that develops COVID-19 research initiatives and testing solutions, is conducting the study with support and resources from Air Canada and the Greater Toronto Airports Authority.
The study will collect information from volunteer passengers on international flights to determine the effectiveness of different quarantine periods.
Participation requires travellers to provide a sample to MHL researchers before leaving the airport and supply two additional samples that will be self-collected seven and 14 days after arrival.
Verto Health's solution, which solves the decades-old problems of healthcare platform interoperability and care coordination, is being leveraged by MHL to provide data connection and data collection technology, workflow and forms automation.
Verto Health's software will connect data from the passenger testing data collection point to the lab, and communicate results back to the participant.
The company's workflow and forms automation will allow passengers' data to be made anonymous, and for them to be notified of their results within 48 hours of taking the test.
Integrating workflows from different healthcare systems typically takes months and involves moving data from various sources.
Because Verto's digital twin platform leaves information where it already resides, and links to it instead, the software can establish information workflows between systems within weeks.
The highly scalable solution, which currently integrates with more than 75 hospitals and healthcare organizations, can be implemented without disrupting existing EMR or legacy systems.
Through the use of MHL research protocols and a highly secure platform, participants' data will be collected anonymously and managed in accordance with the same security and privacy regulations as hospitals and other healthcare organizations.
Personal information of the study participants will be processed and stored in Canada at all times and protected from disclosure.
Verto is fully compliant with PIPEDA, PHIPA and HIPAA regulations.
McMaster HealthLabs is a non-profit organisation that develops COVID-19 research initiatives and testing solutions to keep Canadians safe and to get them back to work.
MHL works with scientists and doctors from McMaster University, the Research Institute of St. Joe's Hamilton, and other Canadian universities and research organizations.
MHL is focused on curbing the human, economic and social costs of COVID-19 by creating scientific research initiatives that help Canadian leaders make evidence-based decisions.
Verto Health is a team of passionate healthcare informaticians and technologists working to use digital twin technology to revolutionise interoperability, health delivery efficiency and cross-sector collaboration with the ultimate goal of dramatically improving patient outcomes and the patient experience, all while significantly reducing administration and healthcare organisation costs.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA